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Abstract
Background: The reverse treatment of patients with synchronous colorectal liver metastases (CRLM) is a sequential
approach with systemic chemotherapy first, followed by liver resection, and finally, primary tumor resection. The
aim of this study was to assess the feasibility, the radiological and pathological tumor response to neoadjuvant
therapy, recurrence rates and long-term survival after reverse treatment in a cohort study.
Methods: Data from patients with CRLM who underwent a reverse treatment from August 2008 to October 2016
were extracted from our prospective hepato-biliary database and retrospectively analyzed for response rates and
survival outcomes. Radiological tumor response was assessed by RECIST (Response Evaluation Criteria In Solid
Tumor) criteria and pathological response according to TRG (Tumor Regression Grade). Disease-free and overall
survival were estimated with Kaplan-Meier survival curves.
Results: There were 44 patients with 19 rectal and 25 colonic tumors. The reverse treatment was fully completed
until primary tumor resection in 41 patients (93%). Radiological assessment after chemotherapy showed 61% of
complete/partial response. Pathological tumor response was major or partial in 52% of patients (TRG 1–3). Median
disease-free survival after primary tumor resection was 10 months (95% CI 5–15 months). Disease-free survival at 3
and 5 years was 25% and 25%, respectively. Median overall survival was 50 months (95% CI 42–58 months). Overall
survival at 3 and 5 years was 59% and 39%, respectively.
Conclusion: The reverse treatment approach was feasible with a high rate of patients with complete treatment
sequence and offers promising long-term survival for selected patients with advanced simultaneous colorectal liver
metastases.
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Background
At the time of diagnosis, up to 20% of patients with
colorectal cancer have simultaneous liver metastases [1].
In addition to treat the primary tumor, complete resec-
tion of colorectal liver metastases (CRLM) is mandatory
to provide a curative treatment [2]. Development of new
anti-cancer drugs and their combination with anti-VEGF
and/or anti-EGFR agents increased the major tumor re-
sponse rate up to 72% [3–7], thus offering to new treat-
ment strategies. High response rates to chemotherapy
offer the potential of curative treatment after downsizing
CRLM for patients with initial unresectable disease. The
traditional treatment (“classic”) consists in a staged ap-
proach with resection of the primary colorectal tumor,
followed by systemic chemotherapy and liver resection.
The reverse treatment or liver-first approach, first de-
scribed by Mentha in 2006, was based on initial neoadju-
vant chemotherapy, followed by liver resection and
finally, primary tumor resection [8]. The rationale of this
strategy was to target liver metastases first, thus avoiding
their progression during treatment of the primary
tumor, especially for patients with multiple or large
CRLM. The precise selection criteria for choosing clas-
sical or reverse strategies were not clearly defined, and
none of these have until now shown any survival advan-
tage [9]. The reverse treatment approach has been used
at our institution since 2008. The study aim was to as-
sess the feasibility and completion rate of liver-first
treatment, radiological and pathological tumor response
to neoadjuvant chemotherapy, as well as overall and
disease-free survival.
Methods
Study design
Retrospective analysis of prospectively collected data on
consecutive patients who underwent liver resection for
CRLM within a reverse treatment at our institution from
August 2008 to October 2016. Selection criteria for re-
verse treatment was synchronous CRLM with predomin-
ant hepatic disease with no bowel occlusion at initial
presentation as evaluated and validated during multidis-
ciplinary tumor board. Exclusion criteria for a liver-first
approach were: metastases not located in the liver or lung,
persistent unresectable liver metastases after neoadjuvant
chemotherapy, and more than 3 pulmonary metastases.
Patients with refusal of consent were not included and
written consent was obtained for all participants.
This study was approved by the local ethical commit-
tee (2016–01286) and conducted in accordance with the
STROBE criteria (http://strobe-statement.org/).
Treatment strategy
A reverse treatment was defined as sequential manage-
ment with neoadjuvant chemotherapy, hepatic resection,
and then resection of the primary colorectal cancer. Fol-
lowing neoadjuvant chemotherapy, radiological reassess-
ment with contrast-enhanced CT and/or liver MRI was
performed after 2 to 6 cycles of treatment to evaluate
the response of CRLM according to the response evalu-
ation criteria in solid tumors (RECIST) [10]. Liver resec-
tions were performed by experienced hepatobiliary
surgeons with curative intent. Intraoperative ultrasound
was used to guide the resection. Primary tumors were
resected after complete hepatic clearance. In case of pul-
monary metastases, they were treated after hepatic and
primary tumor resection. The need for adjuvant chemo-
therapy was discussed at our multidisciplinary tumor
board. The oncological follow-up was carried out by on-
cologists or surgeons, with at least monitoring of CEA,
thoraco-abdominal CT every 3 months for the first year,
and then every 6months and liver MRI every 6 months.
Outcome measures
Postoperative complications within 30 postoperative
days were prospectively collected in our hepatobiliary
and colorectal databases. Mortality was assessed after 30
and 90 postoperative days. The Clavien classification
[11], grading the most severe complication of each pa-
tient, and the Comprehensive Complication Index (CCI)
[12], an index calculated by adding each complication
weighted for its severity, were reported. Major complica-
tions were defined as Clavien grade 3 or 4.
Radiological response to neoadjuvant treatment ac-
cording to RECIST criteria was systematically reevalu-
ated by a senior radiologist (PB). Pathologic data were
independently re-analyzed for purpose of the present
study by two pathologists, one senior with gastro-
intestinal and hepatobiliary expertise (CS) and one
junior involved in gastro-intestinal and hepatobiliary
pathology (CR). All archival slides (from formalin-fixed
paraffin-embedded tissue) were reviewed, blinded from
the rest of the study. Forty-four cases were analyzed,
from which four consultation cases and three local cases
had no colorectal resection material available.
For the liver metastasis specimens, tumor regression
grade (TRG) was assessed in each metastasis according to
Rubbia-Brandt [13]. Non-tumoral liver parenchyma was
analyzed to define the presence of chemotherapy associ-
ated liver injury. The presence of sinusoidal obstruction
syndrome (SOS) was graded according to Rubbia-Brandt
[14]. The presence of steatosis and steato-hepatitis was
evaluated and fibrosis was graded according to the
METAVIR score [15].
For the colorectal resections specimens, TRG was
assessed according to Mandard (TRG 1 to 5, with TRG
1 corresponding to complete regression with absence of
histologically identifiable residual cancer and fibrosis)
[16]. In the peri-tumoral region, the amount of fibrosis
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and inflammation was evaluated in 3 grades (1: low; 2:
moderate 3: abundant). For patients with multiple liver
metastases and different TRG, the worse metastasis
(lowest response) was used for TRG categorization [13].
Follow-up method
Follow-up was made on a medical chart basis. In case of
missing data due to outwards follow-up of the patient, the
treating oncologist was contacted by mail for an update.
Disease-free survival (DFS) was calculated from the day of
the primary cancer resection. Overall survival (OS) was
calculated from the day of the primary diagnosis.
Statistical analysis
Categorical variables were reported as numbers and per-
centages, while continuous variables were reported as
medians and interquartile ranges for non-normally dis-
tributed data, or means and standard deviations for nor-
mally distributed data. DFS and OS were calculated with
the Kaplan-Meier method. Statistical analysis was made
with SPSS statistical software package (SPSS version 23
for windows, SPSS inc., Chicago, IL, USA).
Results
Patients’ characteristics and treatment modalities
A total of 44 patients underwent liver resection in the
setting of reverse treatment; demographics and charac-
teristics are shown in Table 1. Most patients (33/44,
75%) initially had unresectable CRLM, as assessed by
HPB surgeons based on location, size of metastasis and
Future Remnant Liver calculation (FRL).
Chemotherapy regimen were decided by the referring
oncologist on an individualized basis. Patients received a
median of six cycles (range 2–12) of neoadjuvant
chemotherapy, Oxaliplatin or Irinotecan-based (13 FOL-
FOX, 15 FOLFIRI, 4 FOLFIRINOX, 4 XELOX, 8 OCFL),
with adjunction of anti-VEGF antibody (bevacizumab) in
19 patients (43%) and anti-EGFR antibody (cetuximab)
in 16 patients (36%). Three patients (7%) received both
bevacizumab and cetuximab. Thirteen (30%) patients
were initially treated with palliative chemotherapy and
referred to our center because of good response to treat-
ment. Radiological reassessment was performed after a
median of 4 cycles of chemotherapy (range 2–6) with
chest and abdominal CT scan and liver MRI.
Eighteen patients (41%) needed portal vein
embolization to increase FRL volume. One patient
underwent simultaneous hepatic vein and portal vein
embolization. For additional small metastases, 11 pa-
tients underwent thermoablation (radiofrequency or
microwave), either preoperatively (n = 3, 6%), during
liver surgery (n = 5, 11%) or both (n = 3, 6%).
Three patients (7%) presented pulmonary metastases
at the time of diagnosis. Neoadjuvant chemotherapy in-
duced complete response of the lung lesions in 2 pa-
tients. The third patient underwent lung wedge
resections following resection of the primary tumor.
Liver-first treatment feasibility
Forty-one out of 44 patients (93%) completed the treat-
ment until primary tumor resection. The three patients
who could not complete the treatment had early meta-
static recurrence. The median interval between the end
of chemotherapy and liver resection was 5.7 weeks
(range: 2.1–19.7 weeks). Longer intervals were seen for
patients referred by external oncologists after good re-
sponse to palliative chemotherapy. For patients who
underwent the whole treatment, median interval be-
tween liver and colorectal surgery was 9.7 weeks (range:
3.5–34.1 weeks).
Bowel occlusion was experienced by five patients
(11%). Two patients needed tumor stent placement and
another two needed diverting stoma because of occlusive
symptoms during neoadjuvant chemotherapy. One pa-
tient needed a Hartmann’s procedure for bowel occlu-
sion after liver resection. Among the 19 patients with
rectal tumors, 13 had preoperative radiotherapy: 4 long
course (25 × 2 Gy) and 9 short course (5 × 5 Gy) treat-
ments. Twenty-three patients (52%) received adjuvant
chemotherapy after primary tumor resection.
Liver and colorectal surgeries
Twenty-seven patients (61%) underwent major liver re-
section, involving three or more liver segments
(Table 2).
Colorectal surgeries were performed in our institution
(n = 33, 80%) or outwards (n = 8, 20%) (Table 2). Colo-
rectal resections were mainly performed by laparoscopy,
with 28 laparoscopic approaches (68%), 9 open surgeries
(22%), and one conversion (2%) due to adherent status
with hepatic laceration during mobilization of the right
colon. Data were missing for 3 patients with outwards
operations.
Table 1 Preoperative characteristics of patients with
synchronous CRLM and selected for a reverse strategy
N = 44
Age (y, median) 63 Range 23–78
Gender (M: F) 28: 16
Primary tumor location Colon 25 57%
Rectum 19 43%
Number of CRLM (median) 5 Range 1–30
Bilobar liver disease 30 68%
Size of largest CRLM (mm, median) 50 Range 9–151
Initial CEA (μg/l, median) 24.8 Range 0.6–1300
CRLM colorectal liver metastasis; CEA carcinoembryonic antigen.
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No mortality occurred within 90 days after liver and
colorectal surgery.
Radiological and pathological response
Radiological response to chemotherapy according to the
RECIST criteria was mainly partial response (n = 27,
61%) or stable disease (n = 12, 27%) (Table 3). One
young patient with progressive disease at first evaluation
received additional preoperative cycles of chemotherapy,
which stopped further tumor growth and adjuvant treat-
ment after hepatectomy. Liver histological response to
neoadjuvant treatment was major or partial (TRG 1–3)
in 23 patients (52%). Analysis of the non-tumoral liver
parenchyma showed chemotherapy-related complica-
tions in 36 patients (81%) (Table 3). The R0 resection
rate was 61%.
Primary tumor response assessment according to
Mandard revealed 7% (3/41) of major responses (TRG
1–2), 15% (6/41) of TRG 3 and 66% of poor response
(TRG 4–5). Tissue for TRG analysis was not available in
5 (12%) patients. TNM stage was as following: 1 ypT0, 1
ypT1, 5 ypT2, 23 ypT3, 7 ypT4. There were 10 ypN0, 17
ypN1, 10 ypN2. R0 resection was achieved in 35 patients
(95%). Tissue for TNM analysis was not available in 4
patients (10%).
Survival
Median follow-up from time of diagnosis was 30.5months.
On an intention-to-treat basis, median OS from time of diag-
nosis was 50months (95% CI 42–58), as shown in Fig. 1.
Table 2 Perioperative characteristics and postoperative
complications for liver and colorectal resection
Liver Surgery N = 44
Type of surgery Right hepatectomy 10 23%
Left hepatectomy 6 14%
Extended right
hepatectomy
8 18%
Extended left
hepatectomy
3 7%
Sectionectomy 7 16%
Bisegmentectomy 1 2%
Segmentectomy 5 11%
Wedge 4 9%
30-day
complications
Minor (Clavien < 3) 9 20%
Major (Clavien ≥3) 14 32%
30 and 90-day
mortality
0
CCI (median,
range)
29.3 8.7–
60.8
Liver specific
complications
Liver failure 6 14%
Biliary leak 9 20%
Colorectal
surgery
N =
41
Type of surgery Right colectomy 6 15%
Left colectomy 3 7%
Sigmoidectomy 12 29%
Hartmann’s
procedure
1 2%
Rectal resection 4 10%
LAR 15 37%
30-day
complications
Minor (Clavien < 3) 10 24%
Major (Clavien ≥3) 6 15%
30 and 90-day
mortality
0
CCI (median,
range)
20.9 8.7–
83.4
CCI comprehensive complication index; LAR Low anterior resection.
Table 3 Radiological and pathological response to neoadjuvant
chemotherapy and description of chemotherapy-related liver
complications
N = 44
Radiological response (RECIST) CR 0 0%
PR 27 61%
SD 12 27%
PD 1 2%
n.a. 4 9%
Pathological response a TRG 1 1 2%
TRG 2 12 27%
TRG 3 10 23%
TRG 4 17 39%
TRG 5 4 9%
Chemotherapy-related liver injury Steatosis 26 59%
Minimal 3
Grade 1 17
Grade 2 2
Grade 3 4
SOS 17 39%
Grade 1 11
Grade 2 6
Fibrosis 16 36%
F1 14
F2 2
Steatohepatitis 15 11%
CR Complete response; PR partial response; SD Stable disease; PD Progressive
disease; n.a N
ot assessed; TRG Tumor regression grade; SOS Sinusoidal
obstruction syndrome.
a Pathological response according to Rubbia-Brandt et al.13 with report of the
worst TRG score in case of multiple metastases with discordant response
between lesions
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Median DFS from time of primary tumor resection was 10
months (95% CI 5–15), as shown in Fig. 2.
Discussion
This cohort study of patients undergoing liver-first ap-
proach for advanced synchronous CRLM revealed a high
completion rate with 93% of patients who underwent
the whole treatment sequence until primary tumor re-
section. The radiological tumor response rate showed
88% of partial response and stable disease according to
RECIST criteria, and the pathological tumor response
was 52% of major or partial response (TRG 1–3). A
promising median overall survival of 50 months, with a
3-year overall survival of 59% was observed.
The completion rate of 93% in the present study was
even higher than described in previous series (65 and
84%) [17–20]. Feared colonic complications such as oc-
clusion or perforation during neoadjuvant treatment oc-
curred only in 11% of the patients and did not preclude
the completion of the whole sequence provided compli-
cations were adequately treated. The rates of colonic
complications found in the literature ranged between 5
Fig. 1 Overall survival from time of diagnosis of all patients who underwent liver resection for colorectal liver metastases as part of a reverse treatment
Fig. 2 Disease-free survival from the time of primary tumor resection of patients who underwent liver resection for colorectal liver metastases as
part of a reverse treatment
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and 7% [17, 20]. Liver surgery was associated with a 52%
morbidity, including 32% major complications. Previous
studies reported morbidity ranging from 17 to 45% [18,
21–28], and major complication rates were 0 to 27.3%
when reported [19, 22–26]. Our high complication rate
could be explained by the aggressive surgical strategy for
patients with high oncologic burden with 40% portal
vein embolization and 61% major hepatectomies, com-
pared to 11–60% portal vein embolization [18, 21, 22,
28, 29] and 36–89% major hepatecomies [18–20, 22–26,
29, 30] in other reports. However, there was no mortality
within 90 postoperative days, while the highest reported
mortality rate of 2% in the series from Welsh et al. [19].
Morbidity after colorectal resection was 39% in the
present study, with 15% major complications, concord-
ant with other series reporting 16.7 to 44.4% overall
morbidity [23, 24, 26].
Radiological response of CRLM to neoadjuvant
treatment was predominantly partial response (61%),
followed by stable disease (27%). These results were
similar to those found in the literature with 3 studies
reporting 5–8% complete response, 68–83% partial re-
sponse, 0–30% stable disease and 8% progressive dis-
ease [18, 26, 30]. Pathological response of CRLM to
neoadjuvant treatment was major or partial (TRG 1–
3) in more than half of the patients (52%). A previous
study also reported the histological response rate
among patients undergoing reverse approach, with
93% (27/29) of TRG 1–3 [31]. The lower histological
response observed in the present study is difficult to
compare as various regimens of neodajuvant chemo-
therapies were used because of referred cases. Histo-
logical response of the primary tumors were major
(TRG 1–2) in 7% and poor (TRG 4–5) in 66%, com-
pared to 35% in each group in the study of Gervaz
et al. with standardized chemotherapy [31]. R0 resec-
tion was achieved in 61% of the patients, which is
comparable with other studies reporting compete re-
section rates of 50–80% [18, 26, 27, 32].
The OS rates were 59 and 39% at 3 and 5 years, re-
spectively, with a median OS of 50 months. These results
were in line with other reports, with a 3 and 5-year OS
of 30 to 89% and 30 to 72%, respectively [19, 21–24, 26,
27, 30, 33]. Nine studies compared the outcomes of re-
verse and classical treatments with similar results in
both groups regarding OS. However these findings need
to be balanced with the fact that there were significantly
more liver metastases [19, 22, 26], larger lesions [27, 28]
and more bilobar spread in the liver-first group [25].
Nevertheless, two studies showed similar OS in both
groups after propensity score matching [27, 29]. The
DFS at 3 years was 25% in the present study, which is
comparable with DFS rates reported in the literature,
ranging from 0 to 31% [18, 26, 27, 33].
Among limitations, the retrospective analysis of pro-
spectively collected data in a single institution presents
its inherent risks of bias of patient selection, missing
data, and loss to follow up. Patients included in the re-
verse treatment were highly selected and only patients
who underwent liver resection for synchronous CRLM
before removal of the primary tumor were included.
Moreover, as a tertiary referral center, some patients
were addressed from other centers after favorable re-
sponse to chemotherapy. Accordingly, data on patients
with intention to reverse approach but who failed to
undergo liver resection were missing. In the same way,
the exact number of patients who were initially consid-
ered as unresectable and who presented a significant re-
sponse allowing a liver resection was not available.
Despite patients’ heterogeneity in terms of chemother-
apy regimens or tumor burden, no subgroup analysis
was performed due to the limited number of patients.
The main weakness of such a study is the absence of
control group. However, as 75% of liver metastasis were
unresctable initially, the only real control group should
not be patient with “classical” treatment sequence (colon
first), but patients with palliative chemotherapy only.
Similar observation may be done on other series [19, 22,
26–28], with some cases of smaller liver metastasis
allowing to choose between reverse or classical treat-
ment, which was not the case in the present series.
Conclusions
In conclusion, the reverse treatment is safe and feasible
with a high rate of patients undergoing the whole
process. With high rate of tumor response during
chemotherapy, the reverse approach allows resection of
both liver and pulmonary metastases, as well as resection
of the primary tumor, with a promising long-term sur-
vival for highly selected patients with advanced syn-
chronous colorectal liver metastases. Therefore, patients
with synchronous colorectal liver metastases, even with
initially unresectable disease, should be discussed in
multidisciplinary board to assess the feasibility of such a
reverse treatment.
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